Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05838287 · ClinicalTrials.gov registry record · Phase 4

Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants

A Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese, sponsored by The University of Texas Health Science Center at San Antonio.

Recruiting
Registry status
Phase 4
Development phase
78
Enrollment target
1
Study location

NCT05838287 is a Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese that is actively recruiting participants, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 78 participants, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05838287, a Phase 4 study of Heart Failure With Preserved Ejection Fraction and Type 2 Diabetes Mellitus in Obese, is actively recruiting participants, sponsored by The University of Texas Health Science Center at San Antonio.

RECRUITING
Registry status
Phase 4
Development phase
78 participants
Enrollment target
1
Study location

Study Summary

Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathophysiologic role in the development of heart failure with preserved ejection fraction (HFpEF) in obese type 2 diabetic (T2D) individuals. 2. To demonstrate that pioglitazone, improves diastolic (as well as systolic) function by improving myocardial insulin sensitivity and by reducing both myocardial and epicardial fat content.

Conditions Studied

Heart Failure With Preserved Ejection Fraction Type 2 Diabetes Mellitus in Obese

Interventions

  • DRUG Placebo
  • DRUG Pioglitazone

Study Locations (1)

Texas

  • Texas Diabetes Institute/UH - San Antonio

Trial Details

FieldValue
Enrollment Target 78 participants
Start Date 2023-07-10
Est. Completion 2030-01
Phase Phase 4

Sponsor

The University of Texas Health Science Center at San Antonio

378 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05838287

The ClinicalTrials.gov registry entry for NCT05838287 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,286-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (97% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05838287 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05838287 about?

NCT05838287 is a clinical study titled "Pioglitazone on Heart Failure in Type-2 Diabetes Mellitus Participants". Our goal of the study is to learn the effects of the diabetes medication named Pioglitazone, in type-2 diabetic obese participants with Heart failure. The main question it aims to answer are: 1. To demonstrate that impaired mitochondrial function leading to reduced ATP generation plays a key pathop...

What is the current status of trial NCT05838287?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 78 participants. The study started on 2023-07-10. Estimated completion is 2030-01.

What conditions does trial NCT05838287 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes Mellitus in Obese.

What interventions are being tested in trial NCT05838287?

The interventions under investigation include: Placebo (DRUG), Pioglitazone (DRUG).

Who is sponsoring clinical trial NCT05838287?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05838287 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction

All registered trials for this condition

Type 2 Diabetes Mellitus in Obese

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.